Lucyoside B

Lucyoside B inhibits the production of inflammatory mediators via both NF-κB and activator protein-1 pathways in activated macrophages[1].

Product Specifications

CAS Number

[91174-19-5]

UNSPSC

12352005

Target

NF-κB

Type

Natural Products

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lucyoside-b.html

Purity

99.21

Solubility

10 mM in DMSO

Smiles

OC[C@H]([C@H]([C@@H]([C@H]1O)O)O)O[C@H]1OC([C@]23[C@](CC(C)(CC3)C)([H])C4=CC[C@@]([C@@]5([C@@]([C@@](C)([C@H]([C@@H](C5)O)O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O)O)O)CO)CO)([H])CC7)C)([H])[C@]7(C)[C@@]4(CC2)C)=O

Molecular Formula

C42H68O15

Molecular Weight

812.98

References & Citations

[1] Yixin Han, et al.Lucyoside B, a triterpenoid saponin from Luffa cylindrica, inhibits the production of inflammatory mediators via both nuclear factor-κB and activator protein-1 pathways in activated macrophages.Journal of Functional Foods, Volume 69, June